

22. (Amended) A compound according to claim 1 wherein

R<sup>1</sup> is selected from the group consisting of hydrogen, halogen and haloalkyl,

R<sup>2</sup> is selected from the group consisting of hydrogen and halogen,

R<sup>3</sup> is a pyrimidine, and

R<sup>4</sup> and R<sup>5</sup> are each hydrogen.

23. (Amended) A compound according to claim 22 wherein

R<sup>1</sup> is trifluoromethyl,

R<sup>2</sup> is hydrogen, and

R<sup>3</sup> is a pyrimidine.

24. (Amended) A compound according to claim 22 wherein R<sup>1</sup> and R<sup>2</sup> are each chloro, and R<sup>3</sup> is a pyrimidine.

## REMARKS

### I. Status of the Claims

Claims 1-27 are pending in the application. Claims 1-3, 5, 7, 12, 14, 17-20, and 22-24 have been amended. Claim 15 is withdrawn from consideration.

Claims 3, 12, 14, and 20 have been amended to correct typographical errors.

Claims 3 and 12 have been amended to replace "<sub>p</sub>(R<sup>12</sup>)" with "(R<sup>12</sup>)<sub>p</sub>." Claims 14 and 20 have been amended to replace "R<sub>10</sub>" and "R<sub>11</sub>" with "R<sup>10</sup>" and "R<sup>11</sup>," respectively, as the superscripted labels have antecedent basis in claim 1.

The other claim amendments are discussed with respect to the claim objection and § 112, second paragraph rejections, below.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

No new matter has been added by these amendments, nor do these amendments raise new issues or necessitate the undertaking of any additional search of the art by the Examiner. Accordingly, Applicants respectfully request reexamination of the claims.

**II. Objection to the claims**

The Examiner has objected to the claims as allegedly "drawn to multiple inventions for reasons set forth in the restriction requirement." *Office Action* at p. 3.

Applicants have amended claims 1, 2, 5, 7, 14, 17-20, and 22-24 to conform with their election in response to the restriction requirement. Specifically, claim 1 has been amended to recite "wherein at least one of R<sup>1</sup> or R<sup>3</sup> is a pyrimidine." Claims 2, 5, 7, 14, 17-20, and 22-24 have been amended to specify that either R<sup>1</sup> or R<sup>3</sup> is a pyrimidine.

Applicants have also amended Claim 7, consistent with their election in response to the restriction requirement, to incorporate the pyrimidine-containing compounds disclosed in the specification. Specifically, claim 7 now recites, in addition, 4-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-morpholine (example 13), 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidin-4-ol (example 14), 4-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-2,5-dimethyl-morpholine (example 15), 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-3-carboxylic acid amide (example 16), 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-4-carboxylic acid amide (example 17), N-Ethyl-N-1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-pyrrolidin-3-yl)-

acetamide (example 18), 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-3-carboxylic acid ethyl ester (example 19), 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester (example 20), 4-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperazine-1-carboxylic acid ethyl ester (example 21), 4-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperazin-1-yl-acetic acid ethyl ester (example 22), (3-imidazol-1-yl-propyl)-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-amine (example 23), 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-4-carboxylic acid (example 24), 4-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-3-carboxylic acid (example 26), 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-3-carboxylic acid diethyl amide (example 27), N-1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-pyrrolidin-3-yl)-acetamide (example 32), 4-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-6-(2-methoxymethyl-pyrrolidin-1-yl)-pyrimidine (example 33), 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-pyrrolidin-3-ol (example 34), (1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-pyrrolidin-3-yl)-carbamic acid *tert*-butyl ester (example 35), isopropyl-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-methyl amine (example 36), and ethyl-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-methyl-amine (example 37).

Accordingly, it is respectfully requested that the objection to the claims be withdrawn.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

**III. Rejections under 35 U.S.C. § 112, second paragraph**

Claims 1-14 and 16-27 stand rejected under 35 U.S.C. § 112, second paragraph for indefiniteness. Applicants respectfully traverse this rejection.

Claim 1 is rejected "because the dotted lines in formula II are not clear." *Office Action* at p. 4. Applicants submit that one of ordinary skill in the art would readily understand that the dotted lines represent optional bonds depending on the particular substituents D, B, Y and Z, *i.e.*, the dotted line indicates that the formula contains a single or double bond. According to claim 1, D, B, Y and Z can be a group such as -O- or -N=. For example, where D, B, Y or Z is -O-, then D, B, Y or Z contains only single bonds; where D, B, Y or Z is -N=, then the dotted line signifies a bond and D, B, Y or Z has a double bond.

Definiteness under 35 U.S.C. § 112, second paragraph is determined from the point of view of one of ordinary skill in the art. M.P.E.P. § 2173.02. ("[T]he examiner must consider the claim as a whole to determine whether the claim apprises one of ordinary skill in the art of its scope."). Because one of ordinary skill in the art would readily understand that the dotted line indicates an optional bond, Applicants respectfully submit that claim 1 satisfies § 112, second paragraph.

The Examiner also rejects claim 1, alleging that "heterocyclyl" is indefinite. Although Applicants disagree that "heterocyclyl" is indefinite from the point of view of one of ordinary skill in the art, to expedite prosecution, claim 1 has been amended to further define heterocyclyl by ring size, heteroatoms, and optional groups. Support for this amendment can be found in the specification at p. 6, line 5 to p. 7, line 9.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

Claims 1-27 are rejected because "there is a vertical line on the right hand side of every page ... overlapping with the claims." Applicants believe this line was the result of a faulty facsimile reproduction. Applicants enclose a clean copy of the Response and Amendment filed on August 23, 2002.

Claim 14 is rejected for lacking a period. Claim 14 has been amended by adding the period. Claim 20 has also been amended by inserting a period.

By these amendments and remarks, Applicants respectfully submit that the claims now satisfy 35 U.S.C. § 112, second paragraph. Accordingly, Applicants respectfully request withdrawal of the rejection.

#### IV. Conclusion

In view of the foregoing amendments and remarks, Applicants respectfully request the reconsideration and reexamination of this application and the timely allowance of the pending claims. If the Examiner believes a telephone conference would be useful in resolving any outstanding issues, he is invited to call the undersigned at (617) 452-1621.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P

By: Maria Bautista  
Maria T. Bautista  
Reg. No. 52,516


Date: July 15, 2003

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

**APPENDIX: MARKED-UP COPY OF CLAIM AMENDMENTS**


1. (Twice Amended) A compound of formula I



or a pharmaceutically acceptable salt or prodrug thereof,

wherein at least one of R<sup>1</sup>[,] or R<sup>3</sup> is a pyrimidine;

R<sup>2</sup>, [R<sup>3</sup>,] R<sup>4</sup> and R<sup>5</sup> are each independently selected from the group consisting of  
hydrogen, halogen, alkyl, haloalkyl, alkoxy, cyano, nitro, cycloalkyl,  
carboxaldehyde, and a group of formula II defined as



subject to the proviso that one or more than one of R<sup>1</sup> or R<sup>3</sup> is a group of  
formula II as defined above;

wherein D, B, Y and Z at each occurrence are independently selected from the  
group consisting of -CR<sup>6</sup>=, -CR<sup>7</sup>R<sup>8</sup>-, -C(O)-, -O-, -SO<sub>2</sub>-, -S-, -N=, and  
-NR<sup>9</sup>-;

n is an integer of zero to three;

$R^6$ ,  $R^7$ ,  $R^8$  and  $R^9$ , at each occurrence, are each independently selected from the group consisting of hydrogen, alkyl, carboxy, hydroxyalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl and carboxyalkyl; and  $R^{10}$  and  $R^{11}$  are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkoxyalkyl, alkoxycarbonylalkyl, carboxyalkyl, hydroxyalkyl, heterocyclyl, heterocyclylalkyl and heterocyclylamino; or  $R^{10}$  and  $R^{11}$  are taken together with N to form a three to seven membered unsubstituted heterocyclyl ring, or a three to seven membered substituted heterocyclyl ring, substituted with one or more than one substituent  $R^{13}$ , wherein  $R^{13}$ , at each occurrence is independently selected from the group consisting of alkyl, alkylene, alkoxy, alkoxyalkyl, cycloalkyl, aryl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylalkylaminocarbonyl, hydroxy, hydroxyalkyl, hydroxyalkoxyalkyl, carboxy, carboxyalkyl, carboxycarbonyl, carboxaldehyde, alkoxycarbonyl, arylalkoxycarbonyl, aminoalkyl, aminoalkanoyl, aminocarbonyl, carboxamido, alkoxycarbonylalkyl, carboxamidoalkyl, cyano, tetrazolyl, alkanoyl, hydroxyalkanoyl, alkanoyloxy, alkanoylamino, alkanoyloxyalkyl, alkanoylaminoalkyl, sulfonate, alkylsulfonyl, alkylsulfonylaminocarbonyl, arylsulfonylaminocarbonyl and heterocyclylsulfonylaminocarbonyl; wherein A is an unsubstituted aryl group, an unsubstituted heterocyclyl group, a substituted aryl group, or a substituted heterocyclyl group, substituted with one or more than one substituent  $R^{12}$ , wherein  $R^{12}$ , at each occurrence, is



independently selected from the group consisting of halogen, alkyl, aryl, haloalkyl, hydroxy, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyalkoxy, hydroxyalkyl, aminoalkyl, aminocarbonyl, alkyl(alkoxyalkyl), aminoalkyl, heterocyclyl, heterocyclalkyl, carboxaldehyde, carboxaldehyde hydrazone, carboxamido, alkoxyalkyl, carboxy, carboxyalkyl, carboxyalkoxy, hydroxyalkylaminocarbonyl, cyano, amino, heterocyclalkylamino, carboxythioalkoxy, carboxycycloalkoxy, thioalkoxy, carboxyalkylamino, trans-cinnamyl and heterocyclalkylaminocarbonyl; and

wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup> and R<sup>13</sup> are unsubstituted or substituted with one or more than one electron donating or electron withdrawing group

wherein the heterocyclyl is chosen from 4-, 5-, 6- and 7-membered rings containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur; the 4- and 5-membered rings have zero to two double bonds and the 6- and 7-membered rings have zero to three double bonds, the heterocycle being optionally substituted with alkyl, halogen, hydroxy or alkoxy substituents,

further wherein the heterocyclyl optionally comprises a group chosen

from:


(i) bicyclic, tricyclic and tetracyclic groups in which any of the above


heterocyclic rings is fused to one or two rings independently

selected from an aryl ring, a cyclohexane ring, a cyclohexene


ring, a cyclopentane ring, a cyclopentene ring, and another monocyclic heterocyclic ring;

(ii) bridged bicyclic groups where a monocyclic heterocyclic group is bridged by an alkylene group optionally selected from



(iii) compounds of the formula  where X\* and Z\* are independently selected from -CH<sub>2</sub>-, -CH<sub>2</sub>NH-, -CH<sub>2</sub>O-, -NH- and -O-, with the proviso that at least one of X\* and Z\* is not -CH<sub>2</sub>-, and Y\* is selected from -C(O)- and -(C(R''))<sub>v</sub>-, where R'' is hydrogen or alkyl of one to four carbons, and v is 1-3.

2. (Twice Amended) A compound according to claim 1 wherein R<sup>3</sup> is the group of formula II




II


wherein R<sup>10</sup>, R<sup>11</sup>, D, B, Y, Z, and n are defined as in claim 1; and

R<sup>1</sup> is defined as in claim 1 with the proviso that if R<sup>3</sup> does not define a pyrimidine, then R<sup>1</sup> is a pyrimidine.

3. (Twice Amended) A compound according to claim 1 of formula III




III



III

wherein  $R^1$ ,  $R^2$ ,  $R^4$ ,  $R^5$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ , D, B, Y, Z, and n are defined as in claim 1;  
and p is an integer of zero to five.

5. (Twice Amended) A compound according to claim 1 of formula IV



IV

wherein D and B are each independently selected from the group consisting of  
-N= and  $-CR^6=$ ;

R<sup>1</sup> is selected from the group consisting of hydrogen, halogen and haloalkyl, with the proviso that if R<sup>3</sup> does not define a pyrimidine, then R<sup>1</sup> is a pyrimidine;

[R<sup>1</sup> and] R<sup>2</sup> ~~[are each independently]~~ is selected from the group consisting of hydrogen, halogen and haloalkyl;

R<sup>10</sup> and R<sup>11</sup> are defined as in claim 1;

R<sup>12</sup>, at each occurrence, is independently selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, carboxyalkoxy, carboxyalkyl and heterocyclyl, wherein R<sup>12</sup> is unsubstituted or substituted with at least one electron donating group or electron withdrawing group; and

p is an integer of zero to five.

7. (Twice Amended) A compound according to claim 1, selected from the group consisting of 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-3-carboxylic acid, 4-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-6-(3-(2*H*-tetrazol-5-yl)-piperidin-1-yl)-pyrimidine, 4-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-6-(4-(2*H*-tetrazol-5-yl)-piperidin-1-yl)-pyrimidine, (1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidin-3-yl)-methanol, 2-(1-(6-(4-(2-isopropylphenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidin-4-yl)-ethanol, [~~N-(1-(4-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyridin-2-yl)-pyrrolidin-3-yl)-acetamide, 1-(4-(4-(2-methoxy-phenylsulfanyl)-3-trifluoromethyl-phenyl)pyridin-2-yl)-pyrrolidine-3-ol, N-1-(4-(4-(2-methoxy-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyridin-2-yl)-pyrrolidine-3-yl)-acetamide, N-1-(4-(4-(2-methoxy-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyridin-2-yl)-~~

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com


~~pyrrolidine-3-yl)-acetamide, N-1-(4-(4-(2-methoxy-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyridin-2-yl)-pyrrolidine-3-yl)-acetamide, N-1-(4-(4-(2-methoxy-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyridin-2-yl)-pyrrolidine-3-yl)-acetamide, 4'-(4-(2,3-dihydro-benzo(1,4)dioxin-6-ylsulfanyl)-3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-(1,2')bipyridinyl-4-carboxylic acid, and 4'-(4-(2,3-dihydro-benzo(1,4)dioxin-6-ylsulfanyl)-3-trifluoromethyl-phenyl)-3,4,5,6-tetrahydro-2H-(1,2')bipyridinyl-3-carboxylic acid]~~ 4-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-morpholine, 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidin-4-ol, 4-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-2,5-dimethyl-morpholine, 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-3-carboxylic acid amide, 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-4-carboxylic acid amide, N-Ethyl-N-1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-pyrrolidin-3-yl)-acetamide, 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-3-carboxylic acid ethyl ester, 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-4-carboxylic acid ethyl ester, 4-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperazine-1-carboxylic acid ethyl ester, 4-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperazin-1-yl-acetic acid ethyl ester, (3-imidazol-1-yl-propyl)-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-amine, 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-4-carboxylic

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

acid, 4-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-  
piperidine-3-carboxylic acid, 1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-  
trifluoromethyl-phenyl)-pyrimidin-4-yl)-piperidine-3-carboxylic acid diethyl amide,  
N-1-(6-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-  
pyrrolidin-3-yl)-acetamide, 4-(4-(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-  
phenyl)-6-(2-methoxymethyl-pyrrolidin-1-yl)-pyrimidine, 1-(6-(4-(2-isopropyl-  
phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-pyrrolidin-3-ol, (1-(6-(4-  
(2-isopropyl-phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-pyrrolidin-3-  
yl)-carbamic acid *tert*-butyl ester, isopropyl-(6-(4-(2-isopropyl-phenylsulfanyl)-3-  
trifluoromethyl-phenyl)-pyrimidin-4-yl)-methyl amine, and ethyl-(6-(4-(2-isopropyl-  
phenylsulfanyl)-3-trifluoromethyl-phenyl)-pyrimidin-4-yl)-methyl-amine.

12. (Amended) A compound according to claim 1 wherein A is an unsubstituted or substituted aryl group of the formula




wherein  $R^{12}$  is defined as in claim 1; and  $p$  is an integer of 0 to 5.

14. (Amended) A compound according to claim 1 wherein  $R^3$  is selected from the group consisting of

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



**R<sup>1</sup> is defined as in claim 1 with the proviso that if R<sup>3</sup> does not define a pyrimidine, then R<sup>1</sup> is a pyrimidine.**


17. (Amended) A compound according to claim 1 wherein

**R<sup>1</sup> is selected from the group consisting of hydrogen, halogen, alkyl and nitro, with the proviso that if R<sup>3</sup> does not define a pyrimidine, then R<sup>1</sup> is a pyrimidine;**

**[R<sup>1</sup> and] R<sup>2</sup> [are each independently] is** selected from the group consisting of hydrogen, halogen, alkyl, and nitro;

R<sup>4</sup> and R<sup>5</sup> are each independently selected from the group consisting of hydrogen and alkyl; and

R<sup>3</sup> is



wherein

D is -CR<sup>6</sup>= or -N=,

B is -S-, -O-, -CR<sup>6</sup>= or -N=,

FINNEGAN  
HENDERSON,  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

Y is  $-\text{CR}^6=$  or  $-\text{N}=\text{}$ ,

Z is  $-\text{CR}^6=$  or  $-\text{N}=\text{}$ ; and

n is zero or one

18. (Amended) A compound according to claim 1 wherein

$\text{R}^1$  and  $\text{R}^2$  are each independently selected from the group consisting of  
hydrogen, halogen, and haloalkyl; ~~and~~

**$\text{R}^3$  is a pyrimidine; and**

$\text{R}^4$  and  $\text{R}^5$  are each independently hydrogen.

19. (Amended) A compound according to claim 1 wherein

**$\text{R}^1$  is selected from the group consisting of hydrogen, halogen and**


**haloalkyl, with the proviso that if  $\text{R}^3$  does not define a pyrimidine,**

**then  $\text{R}^1$  is a pyrimidine;**

~~$[\text{R}^1 \text{ and}] \text{R}^2$  [are each independently]~~ **is** selected from the group consisting of  
hydrogen, halogen, and haloalkyl;

$\text{R}^4$  and  $\text{R}^5$  are each independently hydrogen; and

$\text{R}^3$  is



wherein

D is  $-\text{CR}^6=$  or  $-\text{N}=\text{}$ ,

B is  $-\text{S}-$ ,  $-\text{O}-$ ,  $-\text{CR}^6=$  or  $-\text{N}=\text{}$ ,

Y is  $-\text{CR}^6=$  or  $-\text{N}=\text{}$ ,

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



Z is  $-CR^6=$  or  $-N=$ ; and

n is zero or one.


20. (Amended) A compound according to claim 1 wherein

**R<sup>1</sup> is selected from the group consisting of hydrogen, halogen and haloalkyl, with the proviso that if R<sup>3</sup> does not define a pyrimidine, then R<sup>1</sup> is a pyrimidine;**

~~[R<sup>1</sup> and] R<sup>2</sup> [are each independently are]~~ **is** selected from the group consisting of hydrogen, chloro, and trifluoromethyl;

R<sup>4</sup> and R<sup>5</sup> are each independently hydrogen; and

R<sup>3</sup> is selected from the group consisting of



22. (Amended) A compound according to claim 1 wherein

R<sup>1</sup> is selected from the group consisting of hydrogen, halogen and haloalkyl,

R<sup>2</sup> is selected from the group consisting of hydrogen and halogen, ~~[and]~~

**R<sup>3</sup> is a pyrimidine, and**

R<sup>4</sup> and R<sup>5</sup> are each ~~[independently]~~ hydrogen.

23. (Amended) A compound according to claim 22 wherein

R<sup>1</sup> is trifluoromethyl, ~~[and]~~

$R^2$  is hydrogen, and

$R^3$  is a pyrimidine.

24. (Amended) A compound according to claim 22 wherein  $R^1$  and  $R^2$  are each  
[independently] chloro, and  $R^3$  is a pyrimidine.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER <sup>LLP</sup>

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)